2007
Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer
Pusztai L, Anderson K, Hess KR. Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer. Clinical Cancer Research 2007, 13: 6080-6086. PMID: 17947471, DOI: 10.1158/1078-0432.ccr-07-0809.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsClinical Trials, Phase II as TopicGene Expression ProfilingGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceOligonucleotide Array Sequence AnalysisPharmacogeneticsProbabilityRNA, MessengerTissue DistributionTrastuzumabConceptsPhase II studyPhase II trialII trialII studyBreast cancerTwo-stage phase II trialPhase II clinical trialPhase II trial designPredictors of responseMarker-positive patientsPhase II designUnselected patientsPatient populationClinical trialsTrastuzumab responseInsufficient responseTrial designResponse markersSame drugResponse rateMarker testingPotential predictorsMarker assessmentTrialsPatients
1998
Coexpression of the HER-2 Gene Product, pl85HER-2, and Epidermal Growth Factor Receptor, pl70EGF-R, on Epithelial Ovarian Cancers and Normal Tissues
Bast R, Pusztai L, Kerns B, MacDonald J, Jordan P, Daly L, Boyer C, Mendelsohn J, Berchuck A. Coexpression of the HER-2 Gene Product, pl85HER-2, and Epidermal Growth Factor Receptor, pl70EGF-R, on Epithelial Ovarian Cancers and Normal Tissues. Monoclonal Antibodies In Immunodiagnosis And Immunotherapy 1998, 17: 313-321. PMID: 9790065, DOI: 10.1089/hyb.1998.17.313.Peer-Reviewed Original ResearchConceptsOvarian cancerNormal ovarian epitheliumNormal tissuesOvarian epitheliumTumor cellsAdvanced ovarian cancerEpithelial ovarian cancerFavorable therapeutic indexCombination of antibodiesEpidermal growth factor receptorGrowth factor receptorEpithelial specimensHER-2Normal ovariesP170 expressionP185 expressionTherapeutic indexNeoplastic cellsTumor growthSynergistic cytotoxicityFrozen sectionsCancerTherapeutic activityDifferent antigensMonoclonal antibodies